DHS Analytical Studies No. 39
The Rwandan Health Sector Research Policy (HSRP) policy defines the scope of research in the Rwandan health sector and presents the strategic principles to ensure that the research done in Rwandan health sector will be conducted in a more coordinated manner, promoting research for equity and social ...justice and to benefit the Rwandan community as well as the global community in general. The health sector research policy provides solutions to the challenges which have been identified in health research. It will support and improve Rwanda’s health research environment and create a space and framework in which health research will grow and support improved health outcomes in Rwanda. It gives a clear orientation for dissemination and use of results. For sustainability of health research in Rwanda, foreign researchers are called upon to collaborate with Rwandans with clear capacity building plans.
more
The new Global Strategy aims to achieve the highest attainable standard of health for all women, children and adolescents, transform the future and ensure that every newborn, mother and child not only survives, but thrives.
The humanitarian crisis in Yemen is the worst in the world, with over 80 per cent of the population estimated to be in need of humanitarian assistance. The protracted crisis has displaced millions of Yemenis, placing pressure on host communities with limited capacity to support displaced populations....
more
The Global Health Security Agenda programme develops national capacity to prevent zoonotic and non-zoonotic diseases while quickly and effectively detecting and controlling diseases when they do emerge. The Emerging Pandemic Threats programme improves national capacity to pre-empt the emergence and ...re-emergence of infectious zoonotic disease and to prevent the next pandemic.
Action against emerging pandemic threats is taken through projects on: Avian influenza, Middle East respiratory syndrome, Africa Sustainable Livestock 2050 and Emergency equipment stockpile. With high-impact diseases that jump from animals to humans on the rise, these programmes are reducing the risk to lives and livelihoods from national, regional and global disease spread.
more
CHILD AND ADOLESCENT HEALTH IN THE WHO EUROPEAN REGION:
ADOLESCENT MENTAL HEALTH FACT SHEET
Manufacturers:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) ir...respective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks.
more